E. Berns

2.5k total citations
42 papers, 2.0k citations indexed

About

E. Berns is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, E. Berns has authored 42 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cancer Research, 21 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in E. Berns's work include Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). E. Berns is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Cancer Genomics and Diagnostics (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). E. Berns collaborates with scholars based in Netherlands, Belgium and United States. E. Berns's co-authors include John A. Foekens, J.G.M. Klijn, Iris L. van Staveren, Henk Portengen, S.C. Henzen‐Logmans, J.G.M. Klijn, Ignace Vergote, Jozien Helleman, Maxime P. Look and Peter A. van Dam and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Oncogene.

In The Last Decade

E. Berns

42 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Berns Netherlands	23	1.0k	921	763	488	294	42	2.0k
Rosemary L. Balleine Australia	23	649 0.6×	791 0.9×	481 0.6×	680 1.4×	305 1.0×	58	2.0k
David Y.H. Choong Australia	18	1.3k 1.3×	593 0.6×	521 0.7×	389 0.8×	224 0.8×	25	1.9k
Craig P. Carden United Kingdom	13	1.1k 1.1×	1.1k 1.2×	413 0.5×	288 0.6×	536 1.8×	18	2.1k
T. Tominaga Japan	18	730 0.7×	825 0.9×	720 0.9×	459 0.9×	92 0.3×	82	1.7k
Sten Wingren Sweden	24	701 0.7×	1.0k 1.1×	625 0.8×	581 1.2×	72 0.2×	63	2.1k
Maurice P.H.M. Jansen Netherlands	26	1.3k 1.3×	806 0.9×	1.1k 1.5×	361 0.7×	119 0.4×	66	2.2k
Zhaoqing Fan China	23	787 0.8×	821 0.9×	755 1.0×	850 1.7×	45 0.2×	109	1.8k
Emma Dean United Kingdom	29	1.8k 1.7×	1.4k 1.6×	436 0.6×	147 0.3×	175 0.6×	132	2.7k
Silvia Veneroni Italy	26	1.2k 1.2×	1.2k 1.4×	993 1.3×	280 0.6×	64 0.2×	54	2.4k
Cindy J. Yee United States	14	1.0k 1.0×	473 0.5×	409 0.5×	553 1.1×	320 1.1×	21	1.7k

Countries citing papers authored by E. Berns

Since Specialization

Citations

This map shows the geographic impact of E. Berns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Berns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Berns more than expected).

Fields of papers citing papers by E. Berns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Berns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Berns. The network helps show where E. Berns may publish in the future.

Co-authorship network of co-authors of E. Berns

This figure shows the co-authorship network connecting the top 25 collaborators of E. Berns. A scholar is included among the top collaborators of E. Berns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Berns. E. Berns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kriege, Mieke, Antoinette Hollestelle, Agnes Jager, et al.. (2014). Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. British Journal of Cancer. 111(5). 1004–1013. 49 indexed citations

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2013). CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment. 139(3). 649–655. 21 indexed citations

Kok, Marleen, Rutger H.T. Koornstra, Stella Mook, et al.. (2012). Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. The Breast. 21(6). 769–778. 17 indexed citations

Sieuwerts, Anieta M., Kirsten Ruigrok-Ritstier, Maxime P. Look, et al.. (2011). High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Research and Treatment. 133(3). 937–947. 61 indexed citations

Burger, Henry, et al.. (2010). Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). British Journal of Pharmacology. 159(4). 898–908. 101 indexed citations

Lammers, Laureen A., Ron H.J. Mathijssen, Teun van Gelder, et al.. (2010). The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. British Journal of Cancer. 103(6). 765–771. 48 indexed citations

Foekens, J.A., Yongyu Wang, Johan A. Martens, E. Berns, & J.G.M. Klijn. (2008). The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. Drug Discovery Today. 13(11-12). 481–487. 13 indexed citations

Helleman, Jozien, Maurice P.H.M. Jansen, Theo M. Luider, et al.. (2007). Serum proteomic patterns for ovarian cancer monitoring. International Journal of Gynecological Cancer. 18(5). 985–995. 19 indexed citations

Berns, E., Corneel Coens, Paul van Diest, et al.. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer. 42(15). 2539–2548. 22 indexed citations

10.

Elstrodt, Fons, Winand N.M. Dinjens, Michel Molier, et al.. (2003). Allelotype of 28 human breast cancer cell lines and xenografts. British Journal of Cancer. 89(12). 2289–2292. 15 indexed citations

11.

Burg, M.E.L. van der, S.C. Henzen‐Logmans, J.G.M. Klijn, et al.. (2001). Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. British Journal of Cancer. 85(9). 1359–1367. 75 indexed citations

12.

Verhoog, L.C., A.M.W. van den Ouweland, E. Berns, et al.. (2001). Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. European Journal of Cancer. 37(16). 2082–2090. 52 indexed citations

13.

Berns, E., Iris L. van Staveren, L.C. Verhoog, et al.. (2001). Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. British Journal of Cancer. 85(4). 538–545. 12 indexed citations

14.

Henzen‐Logmans, S.C., M.E.L. van der Burg, Carol Derksen, et al.. (1999). Genetic alterations in ovarian borderline tumours and ovarian carcinomas. European Journal of Obstetrics & Gynecology and Reproductive Biology. 82(2). 147–150. 14 indexed citations

15.

Berns, E., et al.. (1998). Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. British Journal of Cancer. 77(7). 1130–1136. 76 indexed citations

16.

Berns, E., J.G.M. Klijn, W L van Putten, et al.. (1998). p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.. Journal of Clinical Oncology. 16(1). 121–127. 50 indexed citations

17.

Diest, P J van, Peter A. van Dam, S.C. Henzen‐Logmans, et al.. (1997). A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.. Journal of Clinical Pathology. 50(10). 801–804. 175 indexed citations

18.

Berns, E., et al.. (1995). Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. British Journal of Cancer. 72(4). 964–967. 23 indexed citations

19.

Berns, E., John A. Foekens, Wim L.J. van Putten, et al.. (1992). Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification. The Journal of Steroid Biochemistry and Molecular Biology. 43(1-3). 13–19. 41 indexed citations

20.

Henzen‐Logmans, S.C., et al.. (1992). Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. British Journal of Cancer. 66(6). 1015–1021. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact